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Background/aim: Familial Mediterranean fever [FMF] is the most common autoinflammatory disease characterized by inflammatory
attacks of fever and polyserositis. Patients’ quality of life is significantly affected due to recurrent excruciating pain attacks and
complications. This study is performed to evaluate the parameters most affecting patients’ satisfaction from treatment.
Materials and methods: Three hundred and forty-six consecutive patients diagnosed with FMF were enrolled in this study. Current
treatment, acute phase proteins, number, type, and severity of predominant attacks, absenteeism from work/school in the last three
months were recorded, and the participants were asked whether they needed additional treatment to evaluate Patient Acceptable
Symptom State (PASS) status.
Results: Mean age of the overall group was 38.2 ± 11.7 years (62.4% female, 37.6% male). Two hundred and twenty-seven patients were
treated with colchicine, 97 patients with colchicine plus Interleukin-1 (IL-1) antagonist, and 22 only with IL-1 antagonist (67.1%, 26.3%,
6.64% in order). Of the overall group, 33.8% (n = 117) believed to need additional treatment options. Additional treatment need of
patients was significantly affected by work impairment due to attacks, absent days from work, disease activity, the discomfort of patients
during attacks, the number of attacks, and treatment options; but not by the level of acute-phase proteins between attacks.
Conclusion: PASS score is significantly related to clinical parameters and quality of life. Patients’ PASS scores and treatment choices are
notably affected by the severity and frequency of attacks and absenteeism from work/school. Clinical activity and quality of life should
be evaluated at every visit to provide patients’ satisfaction with treatment.
Key words: Familial Mediterranean fever, patient-acceptable symptom state, treatment, patient participation

1. Introduction
FMF is the most common autoinflammatory disorder
characterized by recurrent attacks of fever with many clinical
conditions related to serositis. Increased risk of secondary
amyloidosis, which mainly affects renal and vascular
function in untreated or insufficiently treated patients,
colchicine resistance-intolerance, and incompliance to
follow-up of patients are main obstacles to managing the
disease [1-3]. FMF can significantly impair the quality of
life due to recurrent attacks, severe pain, and fever during
attacks, leading patients to be bedridden during the attack.
For this reason, various quality-of-life standard measures
are frequently used. Patient global visual analog scale (PGVAS) scales are not a rational and objective method, but
the simplicity and reliability may provide useful opinions
about preference-based approaches and quality of life [4].
Autoinflammatory disease activity index (AIDAI) has been
recently used for evaluating the frequency and severity

of attacks, using a single-format disease-adapted patient
diary for hereditary fever syndromes [5]. The Institute of
Medicine acknowledges that shared decision-making is a
central component to patient-centered care, it is essential to
improving quality of care, and it can reduce disparities in
clinical outcomes [6]. Sharing treatment decisions with the
patient is an important element that ensures regular followups and treatment compliance. No data comprehensively
presents the factors affecting the patient’s treatment
satisfaction in FMF. We aim to assess factors of clinical and
laboratory outcomes and factors affecting patients’ decisionmaking about treatment in patients with FMF.
3. Materials and methods
The study was conducted between March and September
2021 in the Rheumatology Clinic of Gazi University
Faculty of Medicine. FMF diagnosis was established
according to Eurofever criteria [7]. Demographic features,
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comorbidities, clinical manifestations, detailed attack
characteristics, treatment responses, disease complications,
family history, laboratory features, and MEFV mutations
were recorded. All patients were prospectively monitored
for the frequency, duration, severity of attacks, PG-VAS
during attack, AIDAI scores, laboratory 2 parameters,
compliance, and adverse effects of therapy and work
productivity as absenteeism and presenteeism on each
visit with 3-to-6-month intervals. Patient-acceptable
symptom state (PASS) is defined as the highest level of
symptom beyond which patients consider themselves
well. Patients were classified as PASS-positive if they were
satisfied with the treatment according to their scores
and PASS-negative if they needed additional treatment.
According to the treatment, the study group was divided
into three divisions: 1. only colchicine, 2. colchicine plus
IL-1 antagonists, and 3. IL-1 antagonist. The third group
had colchicine intolerance due to various reasons such
as diarrhea, elevated liver function test, and cytopenia. A
complete response to colchicine was defined as less than
one attack per 6 months. Colchicine resistance was defined
as one or more attacks per month and elevated acute phase
proteins between the attacks [8]. Interleukin 1 inhibitors
were used in patients with frequent attacks (≥1 attack per
month) and in those with chronic manifestations of disease
or amyloidosis plus remarkable inflammatory activity
indicated by persistent acute phase elevation despite the
maximally tolerated dose of colchicine. In all patients,
the initial IL-1 inhibitor was anakinra and switched to
canakinumab when adverse effects, inadequate response,
allergic reaction, or intolerance were observed with
anakinra, which was approved before canakinumab by the
regulatory authority for pharmacoeconomic reasons, offlabel permission was taken from health authorities when
needed. Ethics committee approved the study.
For quality of life assessment, all patients were asked
for VAS, AIDAI scores, PASS status, frequency, severity,
type and duration of attacks, absent days from work/school
in the last 3 months, and additional treatment needs. The
original AIDAI diary contains 13 items as follows: (a)
fever ≥ 38 °C; (b) overall symptoms; (c) abdominal pain;
(d) nausea/vomiting; (e) diarrhea; (f) headaches; (g)
chest pain; (h) painful nodes; (i) arthralgia or myalgia; (j)
swelling of the joints; (k) eye manifestations; (l) skin rash;
(m) pain relief taken. In the original version of the AIDAI,
11 out of 12 items were scored by the patients/parents as 0
= absent, 1 = minor, 2 = mild, 3 = severe, while fever was
scored as 0 = absent or 1 = present for a total score in a
single day of 0–34 and a month of 31 days of 0–1054 [5].
We also take into account these parameters for the last 1
month and scores between 0 and 372.
All statistical analyses were performed with SPSS v. 17.0
software (SPSS Inc., Chicago, IL, USA). Descriptive values
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were presented by mean (standard deviation, SD) and
median (minimum-maximum), and categorical variables as
percentages. The numeric variables were investigated using
visual (histograms and probability plots) and analytical
(the Kolmogorov–Smirnov test) methods to determine
the distribution of data. Because all numeric parameters
showed abnormal distribution, the Mann–Whitney U and
Kruskal–Wallis tests were used according to the number of
study groups. The chi-squared test is applied for categorical
variables. Post hoc analysis of categorical variables was also
applied with chi-squared test Bonferroni correction. p-values
less than 0.05 was accepted as statistically significant.
3. Results
A total of three hundred and forty-six consecutive patients
diagnosed with FMF were included in this study (216
female, 130 male, mean age 38.2 ± 11.7 years). Patients were
divided into three treatment groups: 1. only colchicine, 2.
combination of colchicine and IL-1 antagonists, and 3.
IL-1 antagonists alone. Treatment groups were compared
about PASS status, AIDAI, patient global VAS scores,
absenteeism from work/school, type-duration-severity of
attacks, and acute-phase proteins.
Table 1 shows the differences between the PASSpositive and PASS-negative groups. There was no
significant difference in sex between PASS-positive and
-negative patients (p = 0.218).
PASS status of patients was also significantly affected
by treatment options (p = 0.025). Seventy-five percent of
PASS-positive patients were using colchicine alone, 21.3%
were using colchicine together with IL-1 antagonist, and
2.8% were using only IL-1 antagonist. Patients using only
colchicine plus IL-1 antagonists were more satisfied with
treatment when compared to other treatment options (p =
0.01 for both). There was no significant difference in PASS
status between only-colchicine and only IL-1–antagonist
treatment groups. Absenteeism due to FMF attacks was
significantly associated with PASS status. Of the overall
group, 29.7% complained about work/school impairment
and absenteeism because of attacks. 18.4% of patients
without workday loss and 52% of those with workday loss
expressed additional treatment need, which was statistically
significant (p < 0.05). AIDAI and VAS scores were also
significantly associated with the PASS score. PASS-negative
patients had significantly higher global VAS and AIDAI
scores (p < 0.05 for both). Interattack C-reactive protein
(CRP) and sedimentation levels were not associated with
PASS status (p = 0.413 and p = 0.671, in order).
AIDAI, PG-VAS, and proteinuria were significantly
different between all study groups (p < 0.001, p = 0. 006, p
= 0.001). CRP and sedimentation levels were not different
(p = 0.743, p = 0.408 in order; Table 2). Subgroup analyses
with the Mann–Whitney U test showed significantly higher
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VAS and AIDAI scores for the patient group treated with
colchicine when compared to colchicine plus anti-IL-1
treatment group (p = 0.005 and p = 0.002). Patients treated

with only IL-1 antagonist showed significantly lower AIDAI
scores than the only-colchicine group and colchicine plus
anti-IL-1 treatment groups (p < 0.001, p = 0.001).

Table 1. Comparison of clinical and laboratory conditions between PASS-positive and -negative patients.
PASS-positive

PASS-negative

p-value

Number of patients

229

117

NA

Age (median, years)

36.5

34

0.141

Sex (female/male)%

65.7%/34.3%

55.3%/44.7%

0.218

Genetic mutation (number of patients)
M694V homozygosity
M694V (if any allele)
M680I (if any allele)
V726A(if any allele)
Other mutations

42
104
46
26
11

12
64
26
14
1

AIDAI score (mean)

2

4

<0.005

Patient global VAS (mean)

4

6

<0.005

Work/study day loss

23.1%

40.6%

<0.005

Treatment(colc/colc plus IL1A/only IL1A)

75.9%/21.3%/2.8%

55.3%/42.6%/2.1%

0.025

Proteinuria (mg/day)

149.57

317.86

0.932

CRP between attacks (mg/L)

4

4

0.413

Sedimentation between attacks (mm/h)

16

17.5

0.671

Attack types (number of patients)
Peritonitis
Pleuritis
Fever (only)
Arthritis
Other

86
43
13
62
25

46
21
6
42
8

NS

NS

AIDAI: autoinflammatory disease activity index, VAS: visual analog scale, colc: colchicine, IL1A: interleukin 1 antagonist, CRP: C reactive protein.
Table 2. Comparison of descriptive parameters between the treatment groups.
Only colchicine

Colchicine plus IL1A

Only IL1A

p-value

Age (median, years)

37

34

38

0.15

Number of patients

227

97

22

NA

Sex (female/male)

66.4%/33.6%

56%/44%

47.8%/52.2%

0.074

Dominant attack

Peritonitis

Fever

Peritonitis

0.847

AIDAI (mean)

3

2

0

0.005

VAS (mean)

5

3

3

0.008

CRP (mg/L)

4

4w

5

0.722

Sedimentation(mm/h)

15

18

13.5

0.145

Proteinuria (mg/day)

71.4

324.8

812.14

0.016

Creatinine (mg/dL)

0.6

0.57

0.82

NS

Percentage of patients with amyloidosis (%)

26.4%

89.6%

100

NA

AIDAI: Autoinflammatory disease activity index, VAS: visual analog scale, colc: colchicine, IL1A: interleukin 1 antagonist, CRP: C reactive protein.
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4. Discussion
The goals of treatment in FMF are improving quality of
life (QoL); reducing the frequency, severity, and duration
of attacks; and preventing long-term damage, particularly
AA amyloidosis by minimizing chronic/subclinical
inflammation. Since the disease is usually diagnosed at an
early age, the long duration of the disease causes difficulty
for close follow-up of patients. Considering the quality of
life and preferences of patients may facilitate adherence to
treatment.
Colchicine is an anchor drug for achieving remission
and avoiding damage [9-11]. Although colchicine is so
effective, it still cannot be used in a significant number of
patients due to intolerance and resistance problems [12]. In
our study group, twenty-three patients were using only IL-1
antagonists because of colchicine intolerance. Major side
effects of colchicine are diarrhea, elevation in transaminases,
and leukopenia. Colchicine intolerance constitutes a
major problem, with almost one-fifth of patients unable to
maintain optimal doses which are described as more than
1.5 mg/day [13] Defining colchicine resistance has always
been challenging. Ozen et al. described a new definition the
patients who have ongoing disease activity while those taking
the maximum tolerated dose of colchicine are referred to
as colchicine-resistant [8]. In our study, all patients treated
with IL-1 antagonist had colchicine resistance. Colchicine
could not be given to some of them [n = 22] besides IL-1
antagonists due to intolerance.
IL-1 antagonists are a promising choice of treatment
for colchicine-intolerant or -resistant patients [14]. All of
the IL-1 antagonists have proven to be an effective choice
for reducing the number of attacks and improving quality
of life with insignificant side effects [15, 16]. Although
clinical experience about the efficacy of IL-1 antagonists is
approved, this opinion is based on small-scale data [17,18].
For this reason, it has been deemed appropriate only to
be used in addition to colchicine until further studies are
conducted [11]. According to our data, patients treated
with IL-1 antagonists showed lower VAS and AIDAI scores
when compared to the only-colchicine group. This data
also supports the previous report which evaluated attack
frequency and VAS scores in patients with FMF and treated
with IL-1 antagonists [15]. Proteinuria was significantly
higher in IL-1–treated groups. This difference may have
arisen because the group to which an IL-1 antagonist was
administered was usually colchicine-resistant patients
whose proteinuria was markedly increased. Moreover,
interattack CRP, sedimentation levels, and VAS scores
did not differ significantly between the two groups using
IL-1 antagonists. From here, it can be discussed whether
additional colchicine treatment is required in all patients
treated with IL-1 antagonists. Elevation of acute-phase
proteins between attacks did not show a significant
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difference between the treatment groups in our study. Since
most patients in the treatment groups were followed closely
in the outpatient clinic, none of them had higher acute
phase proteins between attacks. Increased acute phase
elevation between attacks is positioned as an indication for
ongoing inflammation and colchicine unresponsiveness
in previous reports 4 [19]. From this, we can conclude
that close follow-up of the patient is important in the
management of treatment [3]. Patient involvement in the
process of medication decision-making can enhance patient
satisfaction, understanding, and confidence in decisionmaking [20, 21]. Patient-reported outcome measures
have been used for the assessment of the quality of life in
patients with chronic disabling diseases [22]. PASS has
been shown as a practical test for evaluating disease activity
[23, 24]. PASS status of patients was significantly related
to VAS, AIDAI scores, work/study day loss, and treatment
options. Considering these data, we can postulate that the
factors that are effective in the decision of the patients are
the frequency of attacks and the limitation of work.
Working ability and sustaining employment are
important determining factors for patients’ therapeutic
decisions [25]. Studies revealed compromised work
productivity in many diseases including rheumatoid
arthritis, spondyloarthritis, systemic lupus erythematosus
[26-28]. FMF was also studied and experiencing serositis
attacks and severity of pain during attacks was related to
work impairment in FMF patients [29]. According to our
data, patients’ satisfaction with treatment and PASS scores
were related to work impairment. In addition, patients
with work impairment had higher AIDAI and VAS scores.
Reducing the frequency and severity of the patient’s attacks
can provide preventing absenteeism and thus control
ongoing inflammation by increasing treatment compliance.
Many widely used quality of life scales were applied and
reported for patients with FMF like Short Form 36 (SF-36),
the World Health Organization Quality of Life Scale Short
Form (WHOQOL-BREF), and the Health Assessment
Questionnaire (HAQ) [30-32]. Moreover, a specific scale
is also available for FMF patients, and it showed strong
correlation of clinical status in patients with FMF [33].
Nonetheless, SF-36 was significantly correlated with
severity of disease in patients with FMF and treated with
IL-1 blockers. Bodur et al. revealed that FMF-QoL was
significantly correlated with SF-36 and HAQ and also had
a relationship with severity of FMF attacks [34]. Although
quality of life scales were not evaluated in our study, it can be
postulated that PASS status of patients is also an important
predictive parameter about quality of life. The limitations
of our study can be expressed as the low number of patients
and the inability to document the day of work impairment
numerically. Larger-scale studies to be conducted in this
area may reveal the factors associated with absenteeism
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in FMF more clearly. Our study is original as it is the first
study to evaluate PASS status and work/school day loss
according to treatment groups.
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